The Chip That Counts DownWide moat

Intuitive Surgical (ISRG) — moat facet

The clearest statement of a razor-and-blade model in this collection, written by the company, in its own 10-K.

The single most revealing sentence in Intuitive's 10-K is about a memory chip. Describing da Vinci instruments, it says: "A programmed memory chip inside each instrument performs several functions that help determine how the da Vinci surgical system and instruments work together. In addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures to help ensure that its performance meets specifications during each procedure."1 Most instruments are sterilisable at the hospital and "reusable for a defined number of procedures."

How the toll is collectedSystemplaced,ASP $1.6MInstrumentfittedFirmwarecountseach useCount reachesthe limit$1,825 ofthe next caseGross margin 66.0% in 2025 and 67.8% in the June 2026 quarter.
The expiry date is programmed rather than physical. That is the difference between a wear item and a toll.

Read it as an engineer and it is a validated-life control: a wristed instrument with cables and a working tip degrades, and a manufacturer that has tested it to a specified number of cycles has a duty not to let it run past them. Read it as an investor and it is the clearest statement of a razor-and-blade model anywhere in this collection — the razor decides, electronically, when the blade is finished.

The consequence is that Intuitive's consumable revenue per procedure is not set by wear, negotiation or competition. It is set by a number the company chooses, files with a regulator, and enforces in software it wrote, on hardware only it makes. There is no third-party instrument, no compatible generic, and no reprocessor with access to the chip.

What that buys is visible in the gross margin: 66.0% in 2025 and 67.8% in the June 2026 quarter2, on a business that is mostly manufactured plastic, steel and cable assemblies produced in Sunnyvale and Mexicali3.

The exposure is that the same number can be revised, and has been. Regulators cleared an extension of the Ion catheter from five uses to eight4 — a 37.5% reduction in catheters per hundred procedures, granted by an agency rather than taken by a rival.

Moat trajectory: Narrowing

The firmware limit still works exactly as designed, and Intuitive has now committed to raising the count on selected instruments from the first half of 2027. The most direct measure of the toll is being reduced by the company that owns it.

The number that tests this moat
Reported
Instruments and accessories revenue, latest quarter
$1.73B in Q2 2026, up 18%

The use counter is what makes instruments a recurring purchase. Intuitive is raising the permitted uses on some EndoWrist instruments from 2027; this growth falling behind procedure growth would show that change costing revenue.

Source: Intuitive Surgical Q2 2026 results release ↗
⚠ Threats to the moat
⚠ THREAT 01
The Same Design Choice Is What Attracts a Right-to-Repair Argument
A device that refuses to work after a set count is a device somebody will argue should keep working.
References
  1. ReportedIn addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures to help ensure that its performance meets specifications during each procedure." Most instruments are sterilisable...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedWhat that buys is visible in the gross margin: 66.0% in 2025 and 67.8% in the June 2026 quarter, on a business that is mostly manufactured plastic, steel and cable assemblies produced in Sunnyvale and Mexicali.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  3. ReportedWhat that buys is visible in the gross margin: 66.0% in 2025 and 67.8% in the June 2026 quarter, on a business that is mostly manufactured plastic, steel and cable assemblies produced in Sunnyvale and Mexicali.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  4. ReportedRegulators cleared an extension of the Ion catheter from five uses to eight — a 37.5% reduction in catheters per hundred procedures, granted by an agency rather than taken by a rival.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - consolidated financial statements and notes (balance sheet, cash and investments, property and equipment, lease arrangements, revenue disaggregation by geography, accounts receivable, share-based compensation and share counts) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026